Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer.

CONCLUSION: Pertuzumab provided a more comprehensive inhibition of HER2-driven signalling pathways. When administered together with trastuzumab, pertuzumab represent a significant advancement for the treatment of HER2-positive metastatic breast cancer patients. PMID: 23881722 [PubMed - as supplied by publisher]
Source: Advances in Therapy - Category: Drugs & Pharmacology Authors: Tags: Adv Ther Source Type: research